RAPT Therapeutics Announces Two FLX475 Presentations At The Society For Immunotherapy Of Cancer 2023 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
RAPT Therapeutics, Inc. (NASDAQ:RAPT) announced it will present two posters on its oncology drug candidate, FLX475, at the Society for Immunotherapy of Cancer 2023 Annual Meeting. The presentations will focus on the Phase 2 safety and efficacy of FLX475 and its biological activity as a monotherapy and in combination with pembrolizumab in advanced cancer.
October 18, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RAPT Therapeutics' announcement about presenting data on FLX475 at a major conference could potentially boost investor confidence in the company's oncology pipeline.
Presenting data at a major conference often serves as a platform for companies to showcase their progress and potential. This could lead to increased investor interest and potentially a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100